- Avingtrans
- 12 January 2026 09:39:39
Source: Sharecast
Stuart Gall was joining the group with experience in scaling medical technology businesses from early innovation to market adoption.
He was a founding director of Fusion IP, the university commercialisation company acquired by IP Group for £103m in 2014, and most recently served as chief executive of Intelligent Ultrasound Group.
During his tenure, Intelligent Ultrasound transitioned from a university spin-out into a listed business with global partnerships in medical education and clinical AI, before selling its AI software operation to GE HealthCare for £40m in 2024 and disposing of its simulation business to Surgical Science Sweden in February 2025.
“Avingtrans has an exciting portfolio of companies with world-class disruptive technologies that could transform a number of key medical and industrial imaging markets, and I look forward to working with the respective teams to accelerate their commercial adoption and enhance their value to shareholders,” Gall said.
In his new role, Gall would oversee the strategic development and commercialisation of Adaptix and the Magnetica Group.
Adaptix develops low-dose, point-of-care 3D X-ray imaging systems, while Magnetica focuses on compact, helium-free MRI technology.
The division also includes Scientific Magnets, which specialises in the design and manufacture of bespoke cryogen-free superconducting magnets.
Steve McQuillan, chief executive of Avingtrans plc, said the group was “delighted Stuart has been able to start his role earlier than originally notified to the market”, adding that “his proven track record in guiding technology companies from early innovation through to commercial success will be invaluable as we continue to build the value of our medical and industrial imaging division.”
At 0912 GMT, shares in Avingtrans were up 0.19% at 516p.
Reporting by Josh White for Sharecast.com.